Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double‐blind, controlled trial using urodynamic evaluation. Issue 3 (25th August 2017)

• Record Type: Journal Article
• Authors: Totaro, Angelo; Pinto, Francesco; Pugliese, Dario; Vittori, Matteo; Racioppi, Marco; Foschi, Nazario; Bassi, Pier Francesco; Sacco, Emilio
• Is Part Of: Neurourology and urodynamics. Volume 37:Issue 3(2018:Mar.)
• Page Start: 1031
• Page End: 1038
• Publication Date: 2017-08-25
• Subjects: benign prostatic hyperplasia -- botulinum toxin -- LUTS -- prostate; Urinary organs -- Periodicals; Urodynamics -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1002/nau.23390
• Languages: English
• ISSNs: 0733-2467

Abstract

Abstract : Aims: The injection of botulinum neurotoxin A (BTA) into the prostate represents a minimally invasive treatment in patients with lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia (BPH). We evaluated the effectiveness of BTA in treating patients with BPH unresponsive to combined medical therapy (CMT), using urodynamic investigations. Methods: This is a randomized, placebo‐controlled, double blind trial. Twenty consecutive patients were randomly assigned to receive intraprostatic BTA injection ( n = 10) or saline solution (SS) ( n = 10). Patients in the intervention group (IG) received 200‐300 UI of BTA diluted in 6‐8 mL of SS and injected into the transitional zone. Patients in the control group (CG) were treated with SS alone. Primary endpoint was International Prostate Symptom Score (IPSS). Secondary endpoints were: maximum flow rate (Qmax), postvoid residual volume (PVR), maximum cystometric capacity (MCC), bladder outlet obstruction index (BOOI), safety, quality of life (QoL) score, and Patient Reported Outcome (PROs). Results: All patients in the IG reported subjective improvement starting after 1 month. At 3 months of follow‐up IPSS, QoL, PVR were reduced by 55, 3% ( P < 0.01), and 50% ( P < 0.01), 80, 6%, ( P < 0.01), respectively. Qmax was increased by 68% ( P < 0.01). MCC increased by 27% ( P < 0.01) and BOOI decreased by 54% ( P < 0.01). PROs analysis revealed that 90% of patients in the IG reported a subjective symptomatic relief and treatment satisfaction. No local or systemic side effects were observed in any group. Conclusions: These results indicated that intraprostatic BTA is safe and can improve LUTS and QoL in patients with BPH and unsatisfactory response to CMT.